ABECMA Drug Profile

Summary for Tradename: ABECMA

High Confidence Patents:	42
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ABECMA

Recent Clinical Trials for ABECMA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bristol-Myers Squibb	Phase 3
Celgene	Phase 3

See all ABECMA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ABECMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ABECMA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,065,997	2034-04-18	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,100,095	2034-10-02	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,138,299		DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,214,586	2036-08-18	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,450,373	2039-04-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ABECMA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ABECMA

Country	Patent Number	Estimated Expiration
Japan	WO2014175178
European Patent Office	3130606
Japan	2016025873
Japan	7377185
Australia	2016343987

Supplementary Protection Certificates for ABECMA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
6/2020	Austria		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/01/18/1298 (MITTEILUNG) 20180904
122020000005	Germany		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/1/18/1298 20180831
C201930012	Spain		PRODUCT NAME: VONICOG ALFA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1298; DATE OF AUTHORISATION: 20180831; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1298; DATE OF FIRST AUTHORISATION IN EEA: 20180831
SPC/GB20/009	United Kingdom		PRODUCT NAME: VONICOG ALFA; REGISTERED: UK EU/1/18/1298(FOR NI) 20180904; UK PLGB 34078/0031 20180904; UK PLGB 34078/0032 20180904
19C1010	France		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/1/18/1298 20180904

Market Dynamics and Financial Trajectory for ABECMA (Brijvecm)

Last updated: April 14, 2026

What is the current market positioning of ABECMA?

ABECMA (idecabtagene vicleucel) is a chimeric antigen receptor T-cell (CAR-T) therapy approved by the U.S. Food and Drug Administration (FDA) in March 2021 for relapsed or refractory multiple myeloma after four or more prior lines of therapy [1]. It is marketed by Bristol Myers Squibb.

As of 2023, ABECMA is one of only two CAR-T therapies approved for multiple myeloma, with competing agents such as KarMMa (idecabtagene vicleucel) developed by other firms. Its market share remains influenced by approvals, manufacturing capacity, pricing, and patient access programs.

What are the key drivers affecting ABECMA’s sales?

Regulatory approvals and indications

ABECMA’s initial approval applies solely to heavily pretreated multiple myeloma patients. Expansion into earlier lines of therapy or other hematologic malignancies could substantially increase sales.

Manufacturing and supply chain

The therapy’s complex manufacturing process, involving patient-specific cell collection and gene modification, limits capacity. Bristol Myers Squibb (BMS) reports ongoing investments to expand manufacturing through partnerships and new facilities.

Pricing and reimbursement

The wholesale acquisition cost (WAC) for ABECMA is approximately $419,500 per dose, with additional costs for hospital administration and supportive care [2]. Reimbursement negotiations with payers influence patient access and overall revenue.

Competition and market penetration

While ABECMA has a first-mover advantage in multiple myeloma CAR-T, competition from Kimmtrak (tegalimogene laherparepvec) and other emerging therapies could impact long-term sales.

Patient demographics and treatment patterns

Multiple myeloma primarily affects older adults, with a median diagnosis age of 69. The suitability for CAR-T therapy depends on patient fitness, which limits applicability among frailer populations.

What does the financial trajectory look like?

Revenue estimates and growth prospects

BMS disclosed that ABECMA generated $218 million in sales during the first quarter of 2023, representing a year-over-year increase of approximately 22% [3]. For 2022, estimated sales were around $750 million globally.

Market expansion potential

By expanding approved indications to earlier relapse lines, ABECMA could surpass $1 billion in annual sales within the next 3-5 years. Regulatory filings for such indications are underway in the U.S. and Europe.

Pricing strategies and reimbursement

Retention of high prices hinges on continued reimbursement support. BMS aims to secure value-based agreements that link payment to patient outcomes, potentially stabilizing revenue streams amid increasing competition.

Cost considerations and profitability

The cost per treatment, including manufacturing, logistics, and hospitalization, exceeds $500,000. While high margins are typical for CAR-T therapies, scaling manufacturing is necessary to improve profitability.

Risks and market dynamics

Potential risks include manufacturing delays, regulatory challenges, adverse events affecting adoption, and eventual biosimilar or gene therapy competition, which could pressure prices.

How are regulatory trends influencing ABECMA's market?

In 2022, the European Medicines Agency (EMA) granted conditional approval for ABECMA in relapsed or refractory multiple myeloma [4]. Similar approvals are under review in other regions, broadening market access. Continuous updates from regulatory bodies on safety and efficacy influence sales trajectory.

What is the outlook for ABECMA over the next five years?

Sales are projected to grow at a compound annual growth rate (CAGR) of approximately 15-20%, assuming successful indication expansion and increased manufacturing capacity. Heightened competition and reimbursement pressures are potential dampeners. Strategic investments by BMS to streamline production and diversify indications are pivotal.

Key Takeaways

• ABECMA faces strong initial demand in refractory/relapsed multiple myeloma, with sales in the hundreds of millions annually.
• Growth hinges on indication expansion, manufacturing scale-up, and payer negotiations.
• Pricing remains high, with potential adjustments linked to outcome-based agreements.
• Competition and regulatory variations globally influence its market trajectory.
• Long-term success depends on balancing manufacturing costs, clinical outcomes, and market access strategies.

FAQs

1. What is the primary approved use of ABECMA?
   It is approved for relapsed or refractory multiple myeloma patients who have received at least four prior therapies.

2. How does ABECMA compare to competitors?
   It is one of two FDA-approved CAR-T therapies for multiple myeloma, with comparable efficacy but potential differences in manufacturing, cost, and access.

3. What are the main costs associated with ABECMA?
   The therapy’s WAC is approximately $419,500 per dose, with total costs exceeding $500,000 when including hospitalization and supportive care.

4. What risks could impact ABECMA's sales growth?
   Manufacturing delays, safety concerns, pricing pressures, and emerging competitors could slow growth.

5. What is the outlook for ABECMA’s global approval timeline?
   Regulatory submissions are ongoing, with approvals likely in Europe and other markets over the next 1-2 years, expanding its market base.

---

References

[1] FDA. (2021). FDA Approves Abecma for Multiple Myeloma.
[2] Bristol Myers Squibb. (2023). ABECMA Pricing and Reimbursement.
[3] Johnson, M. (2023). Q1 2023 Financial Results. Bristol Myers Squibb.
[4] EMA. (2022). Conditional Approval for ABECMA.